ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Incubator Formed In New York

by Rick Mullin
August 31, 2015 | APPEARED IN VOLUME 93, ISSUE 34

Highline Therapeutics and Weill Cornell Medical College are joining to fund and incubate translational research programs in New York City. The partners hope to establish spin-off companies backed by Versant Ventures, which operates Highline as a biotech incubator. The first program is in the areas of immunology and oncology. Larry Schlossman, Weill Cornell’s head of biopharma alliances and research collaborations, says Cornell “will be delivering on our mission to bring new therapies to patients and helping to foster a biotech ecosystem in New York City.”

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment